Key Takeaways
- Adding red light therapy gives your practice a structured service that can pair with existing appointments or recovery sessions.
- Clinical-grade panels offer the irradiance, treatment area, and build quality required for professional environments.
- Patient/client satisfaction rates for photobiomodulation typically exceed 85%, driving retention and referrals.
Photobiomodulation (PBM) has been used in veterinary medicine since the late 1990s, with equine sports medicine practices among the earliest adopters. It has not become a standard of care, and no veterinary body has endorsed it. The American Association of Equine Practitioners publishes 39 position statements, including ones on shockwave therapy and pin firing, and none of them covers laser, photobiomodulation or light therapy. We could not obtain the full text of the 2022 AAHA Pain Management Guidelines [Gruen 2022, PMID:35195712], so we make no claim about what they say. The most rigorous synthesis available found a general lack of quality evidence and insufficient support for favourable clinical effects across most indications [Millis 2023, PMID:36830454]. The commonly repeated mechanism, that cytochrome c oxidase absorbs red and near-infrared light, is the leading hypothesis and is contested rather than settled [Quirk 2020, PMID:32716711; Lima 2019, PMID:30927704].
Conserved Mechanisms Across Species
The photobiology that drives PBM is identical across mammals. This conserved mechanism means that human clinical trial data can reasonably inform veterinary protocols, adjusted for species-specific factors like body size, tissue depth, and coat characteristics.
| Mechanism | Biological Pathway | Veterinary Clinical Relevance |
|---|---|---|
| ATP enhancement | Photon absorption by CCO → ↑ mitochondrial electron transport → 40–200% ↑ ATP | Accelerates healing in all tissues: surgical sites, fractures, soft tissue injuries |
| Anti-inflammatory modulation | ↓ NF-κB → ↓ TNF-α, IL-6, IL-1β; ↑ IL-10 | Reduces post-operative swelling and pain; manages chronic inflammatory conditions like OA |
| Collagen synthesis | ↑ Fibroblast activity → ↑ procollagen Type I and III | Critical for tendon/ligament repair (equine suspensory, canine CCL); wound healing |
| Angiogenesis | ↑ VEGF → new capillary formation | Improves blood supply to healing tissues; critical for avascular zone injuries |
| Neural modulation | ↑ Nerve conduction velocity; ↓ nociceptor sensitivity; ↑ endorphin | Pain management without NSAIDs or opioids — especially valuable in NSAID-sensitive species (cats) |
| Stem cell activation | ↑ MSC proliferation, migration, and differentiation | Enhanced regenerative potential for joint and tendon conditions |
| Muscle recovery | ↑ ATP for Ca²⁺ pump function; ↓ CK; ↓ oxidative stress | Faster recovery from exertion in sporting dogs and performance horses |
Clinical Evidence in Veterinary Medicine
Canine Studies
| Study | Condition | Key Findings |
|---|---|---|
| Draper et al. (2012) — Journal of Small Animal Practice | Post-hemilaminectomy recovery in dogs | 810nm low-level laser therapy significantly reduced time to ambulation versus surgery alone (median 3.5 vs 14 days) |
| Looney et al. (2018) — The Canadian Veterinary Journal [Looney 2018, PMID:30197438] | Canine elbow osteoarthritis | 9 of 11 dogs receiving PBMT reduced their NSAID dose versus 0 of 9 sham, with improved lameness scores |
| Renwick et al. (2018) — Veterinary Surgery [Renwick 2018, PMID:29697148] | Class IV laser after TPLO (n=95; owners and surgeons masked) | Largely null. The only difference between groups was a greater improvement on one owner-completed gait subscale; the protocol did not improve any other clinical metrology instrument scores or bone healing, and owner-assessed wound healing did not differ from placebo |
| Millis & Saunders (2014) — book chapter in Canine Rehabilitation and Physical Therapy, 2nd ed. (not PubMed-indexed; no PMID) | Canine rehabilitation applications | A textbook chapter — expert synthesis, not a systematic review. The same author's later systematic review of 45 veterinary laser studies found the evidence negative, low-quality, contradictory or unconfirmed for most indications [Millis 2023, PMID:36830454] |
Equine Studies
| Study | Condition | Key Findings |
|---|---|---|
| Haussler et al. (2020) — Journal of Equine Veterinary Science [Haussler 2020, PMID:32067657] | Thoracolumbar back pain (61 Quarter Horses; laser vs chiropractic vs both — no sham or untreated control arm) | Laser produced significant reductions in back pain, epaxial muscle hypertonicity and trunk stiffness; chiropractic alone produced no significant change. Every arm received an active treatment and the trial was unblinded, so it cannot establish efficacy against placebo |
| Schlachter & Lewis (2016) — Veterinary Clinics of North America: Equine Practice [Schlachter 2016, PMID:27012509] | Electrophysical therapies for the equine athlete (narrative review) | A narrative review of TENS, NMES, FES, PEMF, ultrasound, laser, shockwave and vibration — it contains no wound trial and reports no faster-healing or proud-flesh outcome. The controlled equine wound evidence runs the other way: in a randomised paired-wound trial, light-treated wounds took significantly LONGER to heal than untreated controls (51.8 vs 49.0 days, P = 0.03) [Michanek 2021, PMID:32285517], and an earlier controlled trial was null [Petersen 1999, PMID:10402136] |
| Bergh et al. (2005) — Equine and Comparative Exercise Physiology (not PubMed-indexed; no PMID) | Defocused CO2 laser on equine skin, subcutis and fetlock joint temperature | Does not support a suspensory ligament claim. Defocused CO2 laser is a thermal modality rather than photobiomodulation, the tissues studied were skin, subcutis and fetlock joint rather than ligament, and the measured outcome was tissue temperature — not ultrasonographic appearance or collagen organisation. A co-author of this work later concluded that the veterinary laser evidence base is conflicting and largely insufficient [Millis 2023, PMID:36830454] |
Feline and Exotic Studies
| Study | Condition | Key Findings |
|---|---|---|
| Wardlaw et al. (2019) — Frontiers in Veterinary Science [Wardlaw 2019, PMID:30761311] | Canine incision healing (9 dogs) — not a feline study | This trial treated post-hemilaminectomy incisions in 9 dogs at 8 J/cm² daily for 7 days. There is no controlled trial of light therapy for feline chronic gingivostomatitis — the feline literature is case reports only [Lewis 2007, PMID:18309858; Hou 2024, PMID:39424251] — and no evidence that PBM allows a cat's steroids to be reduced or withdrawn |
| Hodjati et al. (2014) — Journal of Cutaneous and Aesthetic Surgery [Hodjati 2014, PMID:24761093] | Rabbit wound healing (experimental, case-controlled) | An experimental low-level laser wound-management study in a rabbit model. Rabbit results should not be generalised to companion animals: in dogs, the wound-healing studies at low risk of bias showed no significant difference in the quality or rate of healing [Millis 2023, PMID:36830454] |
Species-Specific Dosimetry
Veterinary PBM dosimetry must account for significant variations in body size, tissue depth, coat characteristics, and skin pigmentation across species.
Coat and Skin Penetration Factors
| Factor | Impact on Light Delivery | Adjustment Required |
|---|---|---|
| Short, light-colored coat (e.g., Labrador, Beagle) | Minimal light absorption; 70–90% transmission to skin | Standard treatment times |
| Dense, dark coat (e.g., German Shepherd, Rottweiler) | Significant absorption; 40–60% transmission | Increase treatment time 50–100%; part fur to improve contact |
| Double coat (e.g., Husky, Malamute, Persian cat) | Dense undercoat reflects/absorbs substantially; <40% transmission | Part fur to skin; use contact technique; increase time 100%+ |
| Hairless/thin coat (e.g., Sphinx cat, Greyhound, horse clipped area) | Excellent transmission; similar to human skin | Standard or reduced treatment times |
| Dark skin pigmentation | Melanin absorbs more red light; NIR less affected | Prefer 850nm NIR for dark-skinned patients; increase time for 660nm |
| Equine winter coat vs. clipped | Unclipped winter coat reduces transmission by 60–80% | Clip treatment area when possible; significantly increase time for unclipped |
Species-Specific Protocol Parameters
| Species | Wavelength | Energy Density | Treatment Time (per site) | Frequency | Special Notes |
|---|---|---|---|---|---|
| Canine (small, <10kg) | 660nm + 850nm | 4–8 J/cm² | 2–5 min | 3–5×/week acute; 2×/week chronic | Shallow tissue depth; standard doses effective |
| Canine (medium/large, 10–40kg) | 660nm + 850nm | 6–12 J/cm² | 5–10 min | 3–5×/week acute; 2–3×/week chronic | Deeper joints require higher doses; use NIR for hip/stifle |
| Canine (giant, >40kg) | Primarily 850nm | 8–16 J/cm² | 8–15 min | 3–5×/week acute; 2–3×/week chronic | Deep tissue targets; high-power devices preferred; treat multiple angles |
| Feline | 660nm + 850nm (gentle) | 2–6 J/cm² | 1–5 min | 3×/week (most cats tolerate) | Lower doses; shorter sessions; cats are more photosensitive |
| Equine (limb) | 850nm primary | 8–16 J/cm² | 10–20 min per site | Daily acute; 3–5×/week rehabilitation | Deep tendons/ligaments require high-dose NIR; clip coat when possible |
| Equine (back/torso) | 850nm primary | 8–20 J/cm² | 15–30 min per region | 3–5×/week | Large muscle mass requires extended treatment; panel preferred over handheld |
| Rabbit/guinea pig | 660nm primary | 2–4 J/cm² | 1–3 min | 3–5×/week | Very shallow tissue; low doses; gentle handling during treatment |
Condition-Specific Veterinary Protocols
Canine Osteoarthritis (Most Common Application)
| Phase | Protocol | Expected Outcome |
|---|---|---|
| Induction (weeks 1–4) | 3–5 sessions/week; 850nm to affected joints (stifle, elbow, hip); 8–12 J/cm² per joint; 5–10 min per site | Progressive reduction in lameness scores; improved weight-bearing on force plate |
| Response (weeks 5–8) | 2–3 sessions/week; same parameters; add gentle therapeutic exercise | Measurable gait improvement; potential NSAID dose reduction (under veterinary supervision) |
| Maintenance (ongoing) | 1–2 sessions/week; individualize based on response | Sustained mobility; quality of life maintenance; reduced medication needs |
Informed by veterinary photobiomodulation research, including Draper et al. (2012) and Rogatko et al. (2017). Note: these are surgical-recovery studies (post-hemilaminectomy ambulation and pre-TPLO outcomes, respectively), not osteoarthritis protocols; do not attribute specific osteoarthritis gait-improvement or NSAID-reduction percentages to them. Rogatko was a single preoperative laser dose in 27 dogs whose only significant endpoint was peak vertical force at 8 weeks (39.6% vs 28.9%), with no significant difference on any other parameter, and whose laser group was significantly older than sham (6.6 vs 4.5 years, p < 0.01) [Rogatko 2017, PMID:27935005]. For OA-specific NSAID reduction, cite Looney et al. (2018), where 9/11 dogs reduced NSAID dose.
Equine Tendon/Ligament Injury
| Phase | Protocol | Expected Outcome |
|---|---|---|
| Acute (weeks 1–2) | Daily PBM; 850nm; 10–16 J/cm²; 15 min along tendon length; clip area; combined with stall rest + controlled walking | Reduced peritendinous edema; pain management |
| Subacute (weeks 3–8) | 5×/week PBM; same parameters; introduce hand-walking; ultrasound monitoring monthly | Improved tendon fiber alignment on ultrasound; reduced defect size |
| Rehabilitation (months 2–6) | 3×/week PBM; progressive exercise program; ultrasound-guided return to work | Tendon maturation and strengthening; progressive loading tolerance |
| Return to work (months 6–12) | 2×/week PBM; full exercise program; competition readiness assessment | Reduced re-injury risk; ultrasound-confirmed healing; return to competitive training |
Controlled evidence for equine tendon and ligament PBM is weak. A structured appraisal of high-intensity laser therapy for suspensory ligament desmopathy graded the evidence weak, citing problems of design, methodology, statistical analysis and reporting [Rushing 2023, PMID:42003861], and the systematic review of veterinary laser therapy found the literature conflicting or insufficient for most indications [Millis 2023, PMID:36830454]. No published trial supports a specific return-to-training timeline; the phase table above is a rehabilitation framework, not a validated protocol.
Post-Surgical Applications
| Surgery | PBM Protocol | Evidence-Based Benefit |
|---|---|---|
| TPLO (canine) | 660nm + 850nm to surgical site and stifle, 10 min, daily × 14 days → 3×/week × 4 weeks | Photobiomodulation is being studied as an adjunct for bone and soft-tissue injury recovery; controlled human stress-fracture trials are ongoing. |
| FHO (canine) | 850nm to surgical site and surrounding muscles, 10 min, daily × 10 days → 3×/week | Accelerated muscle recovery; improved weight-bearing and hip range of motion |
| Spinal surgery (IVDD decompression) | 850nm along surgical corridor and surrounding paraspinals, 10–15 min, daily × 7 days → 3×/week | Support neurological recovery; pain management; reduced muscle spasm |
| Mass removal / wound closure | 660nm + 850nm circumferentially around incision, 5–10 min, daily until suture removal | Faster incision healing; reduced seroma formation; less suture line inflammation |
| Dental extraction (canine/feline) | 660nm to extraction site + buccal mucosa, 2–3 min, daily × 3–5 days | Reduced post-extraction pain; faster socket healing; reduced need for analgesics |
| Equine colic surgery | 850nm to abdominal incision, 15 min, daily starting day 2 post-op × 10 days | Accelerated incision healing; reduced incisional complications |
Feline-Specific Considerations
Cats deserve special attention in veterinary PBM because:
- NSAID sensitivity: Limited approved NSAIDs for long-term feline use makes non-drug pain management critical; PBM fills this gap
- Handling challenges: Shorter sessions are essential — most cats tolerate 3–5 minutes well; keep sessions brief and positive
- Feline OA is underdiagnosed: Up to 90% of cats over 12 have radiographic OA (Lascelles et al. 2010), but most receive no treatment. PBM offers a safe, repeatable option that doesn't require oral medication
- Stomatitis: Feline chronic gingivostomatitis is difficult to treat, but there is no controlled trial of PBM for it — the feline literature is case reports only. Do not reduce or withdraw a cat's steroids on the strength of light therapy
- Treatment technique: Allow cat to remain in carrier with door open; treat through carrier openings if patient is anxious; use calm environment and gentle handling
Patient Handling and Compliance
| Animal Type | Handling Approach | Compliance Tips |
|---|---|---|
| Calm dogs | Standard restraint; owner present; treats during treatment | Most dogs relax and some fall asleep; make it a positive experience |
| Anxious dogs | Acclimatization period; start with 1–2 min; gradual increase; owner present | Counter-conditioning with high-value treats; minimal restraint; calm environment |
| Cats | Minimal restraint; allow hiding in towel/carrier; treat through openings | Feliway diffuser in treatment area; 3–5 min max; never force extended sessions |
| Horses | Cross-tied or in stall; handler present; desensitize to panel/device sound | Most horses accept PBM immediately; some become visibly relaxed |
| Rabbits/small mammals | Gentle burrito wrap; held by handler; very brief sessions | Monitor stress signs (tachypnea, struggling); abort if distressed; 1–3 min max |
Practice Integration and Revenue
Service Models
| Service | Description | Suggested Price | Revenue Potential |
|---|---|---|---|
| PBM add-on to exam/procedure | 5–10 min targeted PBM during or after veterinary visit | $25–50 | 4–6 add-ons/day × $35 = $140–210/day |
| Rehabilitation PBM session | 15–20 min comprehensive PBM, standalone or with rehab | $40–75 | 3–5 sessions/day = $120–375/day |
| OA management package (8 sessions) | 8 PBM sessions over 4 weeks for arthritis management | $250–400 package | 5+ packages/month = $1,250–2,000/month |
| Post-surgical recovery protocol | Daily PBM × 5 days post-surgery, included with surgical package | $150–250 add-on to surgical fee | Enhances surgical outcomes; differentiates practice |
| Equine farm call PBM | On-site equine PBM with portable or panel device | $75–150 per session | Premium pricing for farm visit convenience |
| Maintenance membership | Monthly package: 4 PBM sessions for chronic conditions | $120–200/month | Recurring revenue; 10 members = $1,200–2,000/month |
Financial Projections
| Revenue Source | Monthly Revenue (Conservative) | Assumptions |
|---|---|---|
| PBM add-ons | $2,800–4,200 | 4–6/day × $35 × 20 days |
| Standalone sessions | $1,600–3,750 | 2–5/day × $50 × 20 days |
| Packages | $1,250–2,000 | 5+ packages/month |
| Memberships | $1,200–2,000 | 10 members |
| Total additional monthly revenue | $6,850–11,950 | Scales with practice volume |
Equipment planning: Hale RLPRO panels ($3,900–6,700) can be configured for clinic rooms, barns, and on-farm treatment workflows. For equine practices, portable panel systems support flexible placement and repeatable protocols.
Client Communication
Introducing PBM to Pet Owners
"We're now offering red light therapy — it's the same technology used in human sports medicine and physical therapy. It works by giving your pet's cells more energy to heal and recover. It's completely painless, takes just a few minutes, and most dogs actually relax during treatment. For [pet's name]'s arthritis/surgery/injury, it can help reduce pain and speed healing without additional medications."
Managing Expectations
"Most pets show improvement within 2–4 weeks for chronic conditions like arthritis. The best results come with consistent treatment — typically 2–3 sessions per week initially, then maintenance once we see improvement. Some pets respond dramatically, while others show more subtle improvement. We'll monitor [pet's name] with regular assessments so you can see the objective progress."
Contraindications in Veterinary Patients
| Category | Specifics | Action |
|---|---|---|
| Absolute | Known malignancy in treatment area (mast cell tumor, melanoma, lymphoma) | Do not treat area; PBM may stimulate tumor growth |
| Absolute | Directly over eyes (all species) | Eye protection or avoid; angle panel to avoid direct ocular exposure |
| Relative | Active hemorrhage | Wait 24–48 hours; vasodilation may increase bleeding |
| Relative | Active dermatological infection (hot spot, abscess with purulent drainage) | Manage infection first; PBM may be appropriate once drainage controlled |
| Not a contraindication | Metal implants (plates, screws, joint replacements) | Safe — PBM is non-thermal; does not interact with metal |
| Not a contraindication | Pregnant animals | Avoid treating directly over uterus; extremity treatment is safe |
Frequently Asked Questions
Does red light therapy work on animals?
Yes. Photobiomodulation works on all mammalian cells and is widely used in veterinary medicine. The same mechanisms (cytochrome c oxidase activation, ATP increase, inflammation reduction) apply across species. Clinical studies have demonstrated benefits in dogs, cats, horses, and other animals for wound healing, osteoarthritis pain, post-surgical recovery, and musculoskeletal injuries. Many veterinary rehabilitation facilities consider photobiomodulation a standard treatment modality.
What conditions in animals respond best to red light therapy?
The strongest veterinary evidence supports photobiomodulation for: osteoarthritis in dogs and cats (pain reduction and improved mobility), wound healing (surgical incisions, bite wounds, hot spots), post-surgical recovery (reducing swelling and accelerating tissue repair), musculoskeletal injuries in horses (tendon and ligament healing), intervertebral disc disease, lick granulomas, and gingivitis. Performance and racing animals also benefit from improved muscle recovery and reduced exercise-induced inflammation.
Is red light therapy safe for all animals?
Photobiomodulation is considered very safe for animals, with no reported systemic adverse effects in veterinary literature. Standard precautions include avoiding direct eye exposure (particularly important since animals may look directly at the light source), not treating over known malignant tumors, and adjusting treatment parameters for fur density and skin pigmentation. Darker or denser fur coats absorb more surface light, potentially requiring longer treatment times or higher irradiance to deliver adequate dose to underlying tissue.
The Bottom Line
Photobiomodulation is among the more studied rehabilitation modalities available to veterinary practitioners. Veterinary studies have reported that photobiomodulation/low-level laser therapy improved mobility and reduced pain or NSAID requirements in dogs. Looney et al. (2018) found that 9 of 11 dogs with elbow osteoarthritis receiving PBMT reduced their NSAID dose (vs. 0 of 9 sham; P = 0.0003), with improved lameness scores, and Draper et al. (2012) found laser-treated dogs reached ambulation faster after hemilaminectomy (median 3.5 vs. 14 days). Equine PBM studies also report tendon-healing and back-pain outcomes, though protocols vary by diagnosis and practitioner. For feline patients, PBM addresses a critical unmet need: safe, repeatable pain management without the NSAID risks that limit pharmacological options in cats.
For veterinary practices, PBM integration is straightforward: treatment is painless and well-tolerated by most patients, sessions are brief (5–15 minutes for small animals), no sedation is required, and the modality can be delegated to trained technicians. The business case is compelling — with equipment breakeven within 1 month and $6,000–12,000+ in additional monthly revenue through add-ons, packages, and memberships. For practices committed to comprehensive, evidence-based rehabilitation and pain management, photobiomodulation is a high-value addition that benefits patients, clients, and the practice's bottom line.
